2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
The research topic is appropriate for a realist review Palliative care is a complex intervention that require the active input of individuals, whose role is influenced by other individuals including patients and colleagues. Palliative care services are embedded in other social infrastructures (such as hospitals, hospices and primary care) and affected by institutional and system factors (such as local and national policy guidance and commissioning).
One of the aims of the review is to produce policy relevant recommendations, which is one of the specific aims of realist review. The research question is constructed in such a way as to be suitable for realist analysis, and is sufficiently and appropriately focused
The research questions broadly ask "when" and "how" palliative care provides benefit to children and their families. This was refined further to specifically ask about the mechanisms by which palliative care provides benefit, and the contexts in which these mechanisms are triggered. The review demonstrates understanding and application of a realist philosophy and realist logic that underpins a realist analysis
The review followed Pawson's five stages of realist review, and the RAMESES standards. A realist logic of analysis allowed for contexts, mechanisms and outcomes to be identified in the data, with a focus on generative causation and the subsequent development of CMOCs.
An initial realist programme theory is identified and developed The initial programme theory was derived from policy documents and a systematic review. This was refined and developed through engagement with stakeholders
The search process is such that it would identify data to enable the programme theory to be developed, refined and tested
The search strategy was deliberately broad and extensive, including multiple data sources. Literature searching took place over two years
The selection and appraisal process ensures that sources relevant to the view containing material of sufficient rigour are identified.
A decision was made to include empirical research evidence related to paediatric palliative care, rather than opinion pieces or editorials, to ensure that the included evidence was rigorous. Rich, in-depth data was yielded via the search strategy with data identified to configure CMOs.
The data extraction process captures the necessary data to enable a realist review An iterative process of data coding and extraction took place, with relevant data coded and captured to support specific CMOCs.
The realist synthesis is reported using the items listed in the RAMESES reporting standard for realist syntheses.
The paper has followed the reporting standards. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 
PALLIATIVE MEDICINE AUTHOR SUBMISSION CHECKLIST: When and how does palliative care "work" for children with life-limiting and life-threatening conditions and their families? A realist review. Dr S Mitchell
Please complete this checklist for all papers submitted. Please indicate, very briefly, how this has been addressed. This checklist is a mandatory upload on submission.
Item
Explanation How this has been addressed (briefly, a sentence will suffice) Article title WHY: Because we want readers to find your work.
Have you followed our guidelines on writing a good title that will be found by search engines? (E.g. with methods in the title, use of common words for the issue addressed, no country names, and possibly indicating findings). If your study has an acronym is it included in the title? Have you included our key statements within the body of your paper (after abstract and before the main text is a good place!) and followed our guidelines for how these are to be written? There are three main headings required, and each may have 1-3 separate bullet points. Please use clear, succinct, single sentence separate bullet points rather than complex or multiple sentences.
Key statements included
Keywords
WHY: Because MeSH headings mean it is properly indexed.
Have you given keywords for your study? We ask that these are current MeSH headings unless there is no suitable heading for use (please give explanation in cover letter). https://meshb.nlm.nih.gov/search
MeSH keywords included
International relevance
WHY: We have readers from around the world who are interested in your work.
Have you contextualised your work for an international audience and explained how your work contributes to an international knowledge base? Avoid drawing from policy from one context only, think
Review draws on international literature and addresses an internationally relevant concern
Page 88 of 92 Data (e.g. quotations) for qualitative studies are not included in the word count, and we prefer that they are integrated into the text (e.g. not in a separate table).
Yes

Study registration WHY: Because this means readers understand how you planned your study
Where appropriate have you included details (including reference number, date of registration and URL) of study registration on a database e.g. trials or review database. If your study has a published protocol, is this referenced within the paper?
Reference number and link included
Other study publications?
WHY: So readers can understand the full context of your study
If there are other publications from this study are these referenced within the body of the paper? Please do not reference papers in preparation or submitted, but in-press publications are acceptable.
N/A
Scales, measures or questionnaires
WHY: So readers can understand your paper in the context of this information
If your study primarily reports the development or testing of scales/measures or questionnaires have you included a copy of the instrument as a supplementary file? N/A 
WHY: We will only publish ethically conducted research, approved by relevant bodies
Have you given full details of ethics/governance/data protection approvals with reference numbers, full name of the committee(s) giving approval and the date of approval? If such approvals are not required have you made it explicit within the paper why they were not required. Are details of consent procedures clear in the paper?
Ethical approval not required
Date(s) of data collection
WHY: So readers understand the context within which data were collected
Have you given the dates of data collection for your study within the body of your text? If your data are over 5 years old you will need to articulate clearly why they are still relevant and important to current practice.
Yes, and full list of references
Structured discussion
WHY: So readers can find key information quickly
Papers should have a structured discussion, with sub headings, summarising the main findings, addressing strengths and limitations, articulating what this study adds with reference to existing international literature, and presenting the implications for practice.
Structured discussion guidelines adhered to. So the context is clear, but the main paper succinct for Can you assert that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you. This is original work. It is not being considered for publication elsewhere. 
Case reports WHY: So that participants are protected, and its importance made clear
5
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
7
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
6,9
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
9
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
11
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
7,8
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. 
20,21
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
n/a
RESULTS
Study selection
17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
9-11
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
20,21
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). n/a DISCUSSION Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
20
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
20,21
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.
21,22
FUNDING Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 
